Laurus Labs Ltd

Laurus Labs Ltd Share Price Today: Live Updates & Key Insights

Get insights on Laurus Labs Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Laurus Labs Ltd Share Price Chart

Laurus Labs Ltd Fundamentals

Traded Volume: 14,25,481

Market Cap(Cr): 52,806

Avg Traded Price 985.00

1 Year return 99.98%

Upper Circuit 994.1

Lower Circuit 975.1

P/E TTM 77.00

P/B Ratio 13.00

Traded Value(Cr) 13944.06

EPS TTM 12.670

Book value 12.670

Dividend 0.00%

Laurus Labs Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Laurus Labs Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Laurus Labs Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -1.89%

1M +6.25%

3M +11.66%

1Y +99.98%

YTD +60.33%

Laurus Labs Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Laurus Labs Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 13.76L

Day Before Yesterday 12.89L

1W Avg 18.14L

1M Avg 23.05L

3M Avg 19.44L

Laurus Labs Ltd Technical Details

Laurus Labs Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 971

Support 2 963

Support 3 952

Pivot Point : 982

Resistance 1 990

Resistance 2 1002

Resistance 3 1009

Laurus Labs Ltd Corporate Actions

Laurus Labs Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Laurus Labs Ltd’s capital allocation strategies.

All

Ex-Date 31-Oct-2025 Type D Description 0.80/share@40.00% Record Date 31-Oct-2025 Ratio 40.00

Ex-Date 09-May-2025 Type D Description 0.80/share@40.00% Record Date 09-May-2025 Ratio 40.00

Ex-Date 06-Nov-2024 Type D Description 0.40/share@20.00% Record Date 06-Nov-2024 Ratio 20.00

Ex-Date 08-May-2024 Type D Description 0.40/share@20.00% Record Date 08-May-2024 Ratio 20.00

Ex-Date 02-Nov-2023 Type D Description 0.40/share@20.00% Record Date 02-Nov-2023 Ratio 20.00

Ex-Date 10-May-2023 Type D Description 1.20/share@60.00% Record Date 10-May-2023 Ratio 60.00

Ex-Date 03-Nov-2022 Type D Description 0.80/share@40.00% Record Date 04-Nov-2022 Ratio 40.00

Ex-Date 10-May-2022 Type D Description 1.20/share@60.00% Record Date 11-May-2022 Ratio 60.00

Ex-Date 17-Nov-2021 Type D Description 0.80/share@40.00% Record Date 18-Nov-2021 Ratio 40.00

Ex-Date 11-May-2021 Type D Description 0.80/share@40.00% Record Date 12-May-2021 Ratio 40.00

Ex-Date 08-Feb-2021 Type D Description 0.40/share@20.00% Record Date 09-Feb-2021 Ratio 20.00

Ex-Date 10-Nov-2020 Type D Description 0.80/share@40.00% Record Date 11-Nov-2020 Ratio 40.00

Ex-Date 29-Sep-2020 Type S Description share@1:5.00 Record Date 30-Sep-2020 Ratio 1:5.00

Ex-Date 01-Jul-2020 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 23-Mar-2020 Type D Description 1.50/share@15.00% Record Date 25-Mar-2020 Ratio 15.00

Ex-Date 03-Jul-2019 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 28-Jun-2018 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 06-Jul-2017 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Dividends

Announcement Date 31-Oct-2025 Ex Dividend Date 31-Oct-2025 Dividend(%) 40

Announcement Date 09-May-2025 Ex Dividend Date 09-May-2025 Dividend(%) 40

Announcement Date 06-Nov-2024 Ex Dividend Date 06-Nov-2024 Dividend(%) 20

Announcement Date 08-May-2024 Ex Dividend Date 08-May-2024 Dividend(%) 20

Announcement Date 02-Nov-2023 Ex Dividend Date 02-Nov-2023 Dividend(%) 20

Announcement Date 10-May-2023 Ex Dividend Date 10-May-2023 Dividend(%) 60

Announcement Date 03-Nov-2022 Ex Dividend Date 03-Nov-2022 Dividend(%) 40

Announcement Date 10-May-2022 Ex Dividend Date 10-May-2022 Dividend(%) 60

Announcement Date 17-Nov-2021 Ex Dividend Date 17-Nov-2021 Dividend(%) 40

Announcement Date 11-May-2021 Ex Dividend Date 11-May-2021 Dividend(%) 40

Announcement Date 08-Feb-2021 Ex Dividend Date 08-Feb-2021 Dividend(%) 20

Announcement Date 10-Nov-2020 Ex Dividend Date 10-Nov-2020 Dividend(%) 40

Announcement Date 01-Jul-2020 Ex Dividend Date 01-Jul-2020 Dividend(%) 10

Announcement Date 23-Mar-2020 Ex Dividend Date 23-Mar-2020 Dividend(%) 15

Announcement Date 03-Jul-2019 Ex Dividend Date 03-Jul-2019 Dividend(%) 15

Announcement Date 28-Jun-2018 Ex Dividend Date 28-Jun-2018 Dividend(%) 15

Announcement Date 06-Jul-2017 Ex Dividend Date 06-Jul-2017 Dividend(%) 15

Bonus

No Bonus has been declared by LAURUSLABS

Splits

Record Date 30-Sep-2020 Split Date 29-Sep-2020 Face Value (Before/After) 10.00/2.00

Others

Rights No Rights has been declared by LAURUSLABS

Laurus Labs Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Laurus Labs Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Laurus Labs Ltd's relative performance and valuation against major competitors.

Laurus Labs Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Laurus Labs Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 540.06 Mar 2024 658.54 Mar 2023 881.55 Mar 2022 822.97 Mar 2021 694.45

PARTICULARS Investing Activities Mar 2025 -591.65 Mar 2024 -756.74 Mar 2023 -735.27 Mar 2022 -836.61 Mar 2021 -899.68

PARTICULARS Financing Activities Mar 2025 59.32 Mar 2024 139.41 Mar 2023 -185.19 Mar 2022 15.19 Mar 2021 243.13

PARTICULARS Net Cash Flow Mar 2025 7.73 Mar 2024 41.21 Mar 2023 -38.91 Mar 2022 1.55 Mar 2021 37.90

Laurus Labs Ltd Shareholding Pattern

This shows the ownership breakdown of Laurus Labs Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 27.59%

Public 34.52%

Other Institutions 3.19%

FII 26.17%

Mutual Funds 8.53%

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007. Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016.Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. With 12 manufacturing facilities - 8 operating facilities in Visakhapatnam, a drug substance unit and a kilo lab in Hyderabad, and two bio facilities in Bengaluru - which are accredited by global regulatory agencies, including the US FDA and WHO, Company ensure the highest quality standards in the production processes.The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture and sale of APIs and advanced intermediates; itsGenerics - FDF business comprises the development and manufacture of oral solid formulations; its Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and its ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors. The company has launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma Limited ('NATCO') and Strides Shasun Limited. As of September 30, 2016, the Company owned 34 patents and had 152 pending patent applications, in several countries.The company disinvested its 100% stake in Viziphar Biosciences Private Limited vide Agreement dated April 18, 2016, being the effective date of Agreement as April 1, 2016 and therefore Viziphar Biosciences Private Limited ceased to be the Subsidiary of the Company w.e.f. April 1, 2016. Its dedicated manufacturing facility for Aspen was inaugurated and became operational from November 2016. The company acquired balance 73% of equity shareholding of its Associate Company, namely Sriam Labs Private Limited with effect from November 1, 2016, thereby Sriam Labs Private Limited became 2nd 100% wholly Owned Subsidiary of the Company. Sriam Labs Private Limited is a private limited company based in India and engaged in design, development and manufacture of Active pharmaceutical intermediates and Intermediates to cater to the needs of pharmaceutical industry, in exchange for cash. The Group acquired Sriam Labs Private Limited because it will help realize the anticipated growth opportunities and synergies from combining these businesses.During the year ended 31 March 2017, the company expanded its R&D Centre at Hyderabad. It initiated ARV API supply into the European market. USFDA and WHO-Geneva Inspections at the company's Unit-2 was completed. It signed a contract with Dr. Reddy's Lab for the development and marketing of several anti-retroviral formulations on profit and cost sharing basis. Under Profit sharing arrangement between Laurus Labs and Natco for Hepatitis-C Segment, Natco launched Velpatasvir and Sofosbuvir combination in Nepal and launched in India in May 2017. During the year ended 31 March 2017, Laurus Labs signed manufacturing and supply agreement for Oncology NCE for clinical phase and commercial supplies. During the year under review, the company filed 3 ANDAs with USFDA and one dossier with WHO-Geneva.During the year 2019, the Company commenced commercial operations from Unit 4 and Unit 5.During the year 2019, the company incorporated a step down subsidiary in Germany.During the year 2019, the company's Unit 6 USFDA inspection was completed successfully with one observation. In FY19, Company launched Tenofovir, Metformin in US, Tenofovir in Canada, DLT (a three-product combination product) in LMIC countries under partnership with Global Fund for treatment of HIV/AIDS. Also, it commenced supply to Europe under contract manufacturing. In FY 2020, the Company launched Hydroxychloroquine in the United States. It completed backward integration in gemcitabine oncology API. It initiated TLD supplies for the Global Fund tender.During the year 2021, Company acquired a 72.55% stake in Richcore Lifesciences from two private equity funds, Eight Roads and Ventureast and became its subsidiary. It launched TLE400 in the LMIC market. It partnered with a leading generic player in the EU region for contract manufacturing opportunities. It commenced marketing of in-licensed products. It participated with global fund tenders such as PEPFAR, WHO and various African in-country tenders. It completed four drug product validations, apart from the filing of 27 ANDAs and NDAs. It began construction of large formulation manufacturing block which will be available for commercial use starting Q3 2021. It started 3 new manufacturing blocks for commercial manufacturing of intermediates and APIs. It created additional formulation capacity by de-bottlenecking operations. It acquired a company in South Africa and renamed it as Laurus Generics (SA) Pty Ltd. to cater to the needs to South African Market. It has purchased 18 acres of land in Hyderabad to set up a greenfield Finished Dosage Forms Unit.During the year 2021, Company's wholly-owned subsidiary i.e, Laurus Synthesis Inc., USA merged into Laurus Generics Inc., USA, which was a step down subsidiary of the Company.During the year 2022, Company acquired 26.62% of stake in Immunoadoptive Cell Therapy Private Limited, with around Rs. 46 crore investment. During the period 2021-22, Laurus Ingredients Private Limited, a step down subsidiary of the Company was voluntarily strike off from the Regsiter of Companies. It infused more capital into Laurus Generics Inc., due to increase in operations, to a tune of USD 2 Millions.During the year 2022, it commissioned 1 billion tablets capacity. It signed an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication. It acquired lands for two API manufacturing units in Visakhapatnam and one land parcel in Hyderabad for further expansion and its 100% subsidiary, LSPL has acquired two land parcels for manufacturing in Visakhapatnam and one land parcel for its R&D facility in Hyderabad.During 2022-23, the Company incorporated Laurus Speciality Chemicals Pvt. Ltd., a Wholly Owned subsidiary of Laurus Synthesis Pvt. Ltd. for Specialty Chemicals Business on December 01, 2022. It acquired 26% Stake in Ethan Energy. It commissioned the Unit-2 operation project.The Company launched NexCAR19, India's pioneering CAR-T cell therapy for B-cell malignancies, advancing the frontiers of medical science in FY24. Two GMP production plants for Animal Health business have started production in 2024. The Company commenced the $40 million Phase I construction of a new GMP-grade microbial fermentation commercial facility in Vizag.In September 2024, Laurus Labs inaugurated a cutting-edge R&D facility at IKP Knowledge Park, Telangana. The Company acquired 26% equity in Kurnool Renewables to access 26 MW of renewable energy (Solar + wind) on captive model in April, 2025. Company's associate company ImmunoACT, Mumbai treated around 300 patients suffering with Lymphoma and Lukemia with NexCAR-19 and is the first to launch commercial CAR_T therapy and expanding its facilities to create capacity for over 2000 treatments annually in FY 2025.

Whole Time Director & Chief Executive Officer

CHAVA SATYANARAYANA

Registered office Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

FAX :91-891-3061222

Background

Incorporation Year 2005

Face Value ₹2.00

Market Lot 1

Laurus Labs Ltd Latest News

VIEW MORE NEWS

FAQs on Laurus Labs Ltd